MX2019008233A - Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. - Google Patents

Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.

Info

Publication number
MX2019008233A
MX2019008233A MX2019008233A MX2019008233A MX2019008233A MX 2019008233 A MX2019008233 A MX 2019008233A MX 2019008233 A MX2019008233 A MX 2019008233A MX 2019008233 A MX2019008233 A MX 2019008233A MX 2019008233 A MX2019008233 A MX 2019008233A
Authority
MX
Mexico
Prior art keywords
tumor therapy
nanoconjugates
gold
targeted doxorubicin
doxorubicin
Prior art date
Application number
MX2019008233A
Other languages
English (en)
Spanish (es)
Inventor
Kannan Raghuraman
Zambre Ajit
Upendran Anandhi
Original Assignee
Univ Missouri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Missouri filed Critical Univ Missouri
Publication of MX2019008233A publication Critical patent/MX2019008233A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2019008233A 2017-01-09 2018-01-09 Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. MX2019008233A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762444114P 2017-01-09 2017-01-09
PCT/US2018/012882 WO2018129501A1 (en) 2017-01-09 2018-01-09 Targeted doxorubicin-gold nanoconjugates for tumor therapy

Publications (1)

Publication Number Publication Date
MX2019008233A true MX2019008233A (es) 2019-10-17

Family

ID=62791162

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008233A MX2019008233A (es) 2017-01-09 2018-01-09 Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.

Country Status (12)

Country Link
US (1) US20210015944A1 (enExample)
EP (1) EP3568694B1 (enExample)
JP (1) JP7017258B2 (enExample)
KR (1) KR102568577B1 (enExample)
CN (1) CN110178028B (enExample)
AU (1) AU2018205349B2 (enExample)
BR (1) BR112019013469A2 (enExample)
CA (1) CA3048908A1 (enExample)
ES (1) ES2912286T3 (enExample)
MX (1) MX2019008233A (enExample)
WO (1) WO2018129501A1 (enExample)
ZA (1) ZA201904736B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101887421B1 (ko) * 2016-09-20 2018-08-13 김문혜 체인 구동형 유기질비료 발효 건조장치
CN113797353B (zh) * 2020-06-12 2023-10-20 南京工业大学 一种放化疗联合治疗试剂及其制备方法
CN112494660B (zh) * 2020-12-22 2023-11-21 上海交通大学 纳米靶向药物的制备方法及在治疗胃癌中的应用
US12485484B2 (en) 2022-05-17 2025-12-02 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Seedless synthesis of anisotropic gold nanoflowers with cellular control and drug delivery applications
WO2023242766A1 (en) 2022-06-15 2023-12-21 Alembic Pharmaceuticals Limited Gold nanoconjugates
CN120713846B (zh) * 2025-07-14 2026-03-31 湖南省妇幼保健院 基于铜离子和多柔比星的纳米级配位聚合物NP@DoxCu及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563360A (zh) * 2006-10-20 2009-10-21 益普生制药两合公司 肽-细胞毒性缀合物
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
WO2010014812A2 (en) * 2008-07-30 2010-02-04 The Research Foundation Of State University Of New York Peptide compositions and methods of use
KR101196667B1 (ko) * 2010-04-15 2012-11-02 포항공과대학교 산학협력단 피에이치 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
US9605304B2 (en) * 2011-07-20 2017-03-28 The Hong Kong Polytechnic University Ultra-stable oligonucleotide-gold and-silver nanoparticle conjugates and method of their preparation
JP6693868B2 (ja) * 2013-02-19 2020-05-13 ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ 抗癌化学療法剤用のケージ化された白金ナノクラスタ
PL3089997T3 (pl) * 2013-12-30 2020-09-07 The Curators Of The University Of Missouri Wieloskładnikowe nanomateriały au i metody syntezy

Also Published As

Publication number Publication date
BR112019013469A2 (pt) 2020-01-07
RU2019125167A (ru) 2021-02-09
ES2912286T3 (es) 2022-05-25
CN110178028B (zh) 2021-04-27
ZA201904736B (en) 2021-04-28
JP7017258B2 (ja) 2022-02-08
CN110178028A (zh) 2019-08-27
KR102568577B1 (ko) 2023-08-18
US20210015944A1 (en) 2021-01-21
EP3568694B1 (en) 2022-02-16
WO2018129501A1 (en) 2018-07-12
EP3568694A4 (en) 2020-12-30
RU2019125167A3 (enExample) 2021-09-13
AU2018205349A1 (en) 2019-06-27
AU2018205349B2 (en) 2022-09-29
EP3568694A1 (en) 2019-11-20
JP2020504130A (ja) 2020-02-06
CA3048908A1 (en) 2018-07-12
KR20190104333A (ko) 2019-09-09

Similar Documents

Publication Publication Date Title
PH12019501959A1 (en) Therapeutic rna
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
NZ731467A (en) Anti-tim3 antibodies and methods of use
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
EP4691562A3 (en) Anti-pd-l1 combinations for treating tumors
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
IL267795A (en) Combined treatment for cancer
MX382902B (es) Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
EA201791736A1 (ru) Комбинированная терапия для лечения рака
GEP20217317B (en) Combination therapy for the treatment of cancer
MX379621B (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
IL275517A (en) Combined methods and treatment of cancer
PH12020551543A1 (en) Therapeutic modulators of the reverse mode of atp synthase
TW201613587A (en) Medical treatments based on anamorelin
IL304245A (en) Phospholipid-flaveglin conjugates and methods of using them for targeted cancer treatment
IL266993A (en) Combined therapy for cancer treatment
ZA201904736B (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy
PT3720879T (pt) Terapia de combinação entre anticorpo anti-progastrina e imunoterapia para tratar o cancro
PH12016501838A1 (en) Compounds and their methods of use
IL279591A (en) Cancer treatment methods using combination therapy
SG11202102492PA (en) Combination therapy for the treatment of prostate cancer